Loading search results

Outcome Measures

Primary Outcomes (1)

Intracranial local progression-free survival time (iLPFS)
determined as the time from HA-WBRT+SIB initiation to death, existing intracranial metastases progression, or last follow-up.
From date of enrollment until the date of progression of existing intracranial metastases or date of death from any cause, whichever came first, assessed up to 20 months

Secondary Outcomes (5)

Intracranial progression-free survival time (iPFS)
From date of enrollment until the date of progression of existing or new metastases intracranial or date of death from any cause, whichever came first, assessed up to 20 months
Cognitive function
From enrollment to the end of treatment at 4 weeks
OS (Overall survival)
From date of enrollment until the date of death from any cause, whichever came first, assessed up to 20 months
The cumulative incidence of local intracranial failure
From date of enrollment until the date of progression of existing intracranial metastases， assessed up to 20 months
Cumulative incidence of intracranial failure
From date of enrollment until the date of the progression of existing or new intracerebral metastases assessed up to 20 months

Study Arms (1)

Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost

EXPERIMENTAL

HA-WBRT (30 Gy in 12 fractions, Dmax of the hippocampal volume ≤ 17 Gy, Dmean of the hippocampal volume ≤12 Gy) +SIB (48 Gy in 12 fractions)

Radiation: ippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost

Interventions

ippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated BoostRadiation

hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost

Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 75 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

adults (aged 18-75 years) diagnosed with NSCLC, with a KPS (Karnofsky performance status) ≥70, at least four brain metastases visible on MRI (magnetic resonance imaging) outside a 5-mm margin around the bilateral hippocampi, not suitable for targeted therapy or progressing intracranial post targeted therapy.

You may not qualify if:

MeSH Terms

Conditions

Brain NeoplasmsCarcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Central Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung Diseases

Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost for BMs of NSCLC

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (1)

Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Design

Study Record Dates

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (1)

Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Design

Study Record Dates

Data Sharing

Source record

Locations